Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.58 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.58 |
| ▸ | CYP2J2 | P51589 | 13/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.69 |
| ▸ | HRH1 | P35367 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | APEX1 | P27695 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | HTR2B | P41595 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1395734 | 0.91 | CYP2J2 (0.84) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| Hydrochloric Acid SCHEMBL3681404 | 0.90 | CYP2J2 (0.82) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| SCHEMBL13525525 | 0.90 | CYP2J2 (0.82) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| SCHEMBL18765452 | 0.90 | CYP2J2 (0.82) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| SCHEMBL18765451 | 0.89 | CYP2J2 (0.81) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| Terfenadone SCHEMBL11364486 | 0.89 | CYP2J2 (1.00) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| SCHEMBL11826925 | 0.89 | CYP2J2 (1.00) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| Hydrochloric Acid SCHEMBL11830435 | 0.88 | CYP2J2 (0.98) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| Terfenadone SCHEMBL11801242 | 0.88 | CYP2J2 (0.98) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| SCHEMBL2265221 | 0.87 | CYP2J2 (0.78) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696633-B2 | Process for the preparation of fexofenadine and of intermediates used therein | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| EP-3365327-B1 | PROCESS FOR THE PREPARATION OF FEXOFENADINE AND OF INTERMEDIATES USED THEREIN | SANOFI AVENTIS DEUTSCHLAND (DE) | 2019-11-20 | — | — | EP | disclosed |
| US-20180297951-A1 | PROCESS FOR THE PREPARATION OF FEXOFENADINE AND OF INTERMEDIATES USED THEREIN | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2018-10-18 | — | — | US | disclosed |
| EP-3365327-A1 | PROCESS FOR THE PREPARATION OF FEXOFENADINE AND OF INTERMEDIATES USED THEREIN | Sanofi-Aventis Deutschland GmbH (DE) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017068129-A1 | PROCESS FOR THE PREPARATION OF FEXOFENADINE AND OF INTERMEDIATES USED THEREIN | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2017-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696633-B2 | Process for the preparation of fexofenadine and of intermediates used therein | CYP4F2, CYP4F3, NISCH | PDE4A 726/4885PDE3A 647/4885CYP2J2 186/4885 |
| US-20180297951-A1 | PROCESS FOR THE PREPARATION OF FEXOFENADINE AND OF INTERMEDIATES USED THEREIN | CYP4F2, CYP4F3, NISCH | PDE4A 726/4885PDE3A 647/4885CYP2J2 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.